501O_PR - Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC)

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Sarcoma
Topics Soft Tissue Sarcomas
Aetiology, epidemiology, screening and prevention
Presenter Richard Quek
Citation Annals of Oncology (2016) 27 (suppl_9): ix163-ix168. 10.1093/annonc/mdw597
Authors R. Quek1, H.H. Loong2, V. Sriuranpong3, M. Farid1, S.H. Tan4, W.L. Goh1, S. Mingmalairak3, T.W. Chen5, C. Chang6, A. Pang7, S. Teo7, M.E. Puhaindran8, M.M. Maw9, R. Ngan10, A.K.C. Leung11, J.C. Chan11, T. Hirose12, M. Endo12, A. Kawai12
  • 1Division Of Medical Oncology, National Cancer Center, 169610 - Singapore/SG
  • 2Department Of Clinical Oncology, The Chinese University of Hong Kong, 00000 - Hong Kong/HK
  • 3Division Of Medical Oncology, Department Of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH
  • 4Division Of Clinical Trials And Epidemiological Sciences, National Cancer Center, 169610 - Singapore/SG
  • 5Department Of Oncology, National Taiwan University Hospital, 100 - Taipei/TW
  • 6Department Of Cancer Administration And Coordination Center, National Taiwan University Hospital, 100 - Taipei/TW
  • 7Department Of Haematology-oncology, National University Cancer Institute, Singapore, 119074 - Singapore/SG
  • 8Department Of Hand And Reconstructive Microsurgery, National University Hospital, 119228 - Singapore/SG
  • 9Medical Oncology Unit, University of Medicine 1, Yangon, 11131 - Yangon/MM
  • 10Department Of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong/CN
  • 11Department Of Clinical Oncology, Queen Elizabeth Hospital, NA - Hong Kong/CN
  • 12Division Of Musculoskeletal Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP



Angiosarcoma is an uncommon form of soft tissue sarcoma. Presentation and treatment are heterogeneous. We undertook a multicenter study evaluating the epidemiology, treatment and outcomes of AS pts in 8 sarcoma academic centres across Asia.


This is a retrospective chart review of AS pts seen at the study sites.


In total 423 pts were included into study. Median follow-up was 12.4 mths. 59% and 41% had cutaneous (C-AS) and visceral AS (V-AS) respectively. Median age was 67 yr [74 yr vs 54 yr in C-AS vs V-AS, p 3 lines of chemotherapy. The most common first line chemotherapy regimen was paclitaxel (54%) followed by liposomal doxorubicin (15%). In pts with localized AS who had undergone primary surgery, relapse-free survival was 10.9 mths, 12.9 vs 8.1 mths in pts with C-AS vs V-AS (HR 1.10, P = 0.6). Median overall survival (OS) was 23.7 mths, 24.0 mths in C-AS vs 23.0 mths in V-AS (HR 1.22, P = 0.3). In pts with locally advanced/metastatic AS, median OS on BSC was 1.7 mths vs 17.1 mths for those who received at least 1 line of chemotherapy (HR 5.30, P 


This large observational study in AS is the first collaborative study by the ASC. This study highlights the complexity of AS and heterogeneity of treatment across Asia. Prognosis is poor and optimal treatment remains to be defined.

Clinical trial indentification

Legal entity responsible for the study

National Cancer Centre Singapore




R. Quek: Grants/research support: Novartis Pfizer, Janssen, Bayer and Eisai Honoraria or consultation fees: Novartis, Bayer, BMS, Merck, Roche, Eisai Participation in a company sponsored speaker’s bureau: Novartis, Bayer, Merck, Eisai. V. Sriuranpong: Corporate sponsored research: Novartis, MSD, Astra Zeneca, Roche, Lilly, Sanofi, Pfizer, BMS. All other authors have declared no conflicts of interest.